Stockadora

8-K filings / November 17, 2026

Aldeyra Therapeutics, Inc.: A stock exchange listing notice

Aldeyra Therapeutics, Inc. filed a current report (Form 8-K) with the SEC on November 17, 2026. It reports a stock exchange listing notice.

Item 3.01

Stock exchange listing notice

  • Exchange Nasdaq From the filing
    Source
    “On November 17, 2026, Aldeyra Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice”).”
    Read by code from this sentence of the filing.
  • What it says The company does not meet a listing rule From the filing
    Source
    “On November 17, 2026, Aldeyra Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice”).”
    Read by code from this sentence of the filing.
  • Rule cited Nasdaq Listing Rule 5550(a)(2) From the filing
    Source
    “On November 17, 2026, Aldeyra Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice”).”
    Read by code from this sentence of the filing.
  • Notice date November 17, 2026 From the filing
    Source
    “On November 17, 2026, Aldeyra Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice”).”
    Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov

Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.